Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2023-504910-31-00 | Registry Identifier | EU CT | |
| U1111-1288-3804 | Registry Identifier | UTN | |
| MK-2870-009 | Other Identifier | MSD | |
| jRCT2071240041 | Registry Identifier | Japan Registry of Clinical Trials (jRCT) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs).
The primary hypotheses of this study is that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to overall survival (OS).
Participants will be randomized 1:1 into two arms:
Participants will receive treatment until any of the criteria for discontinuation of study intervention are met.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sacituzumab tirumotecan | Experimental | Participants receive 4 mg/kg sacituzumab tirumotecan via intravenous (IV) infusion every 2 weeks (Days 1, 15, and 29 of every 6-week cycle) until discontinuation criteria is met. |
|
| Pemetrexed Plus Carboplatin | Active Comparator | Participants receive, via IV infusion, 500 mg/m2 pemetrexed every 3 weeks (Days 1 and 22 of every 6-week cycle) plus area under the curve (AUC) 5 mg/mL*min carboplatin every 3 weeks (Days 1 and 22 of every 6-week cycle for 4 doses), then 500 mg/m2 pemetrexed every 3 weeks until discontinuation criteria is met. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sacituzumab tirumotecan | Biological | 4 mg/kg via IV infusion |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival (OS) | Overall survival is defined as the time from randomization to death due to any cause. Overall survival for all randomized participants will be reported. | Up to approximately 51 months |
| Measure | Description | Time Frame |
|---|---|---|
| Progression-Free Survival (PFS) | Progression-Free Survival is defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. PFS for all randomized participants will be reported. | Up to approximately 51 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kaiser Permanente - Oakland ( Site 0054) | Oakland | California | 94611 | United States | ||
| Kaiser Permanente - Roseville ( Site 0055) |
Not provided
| Label | URL |
|---|---|
| Merck Clinical Trials Information. | View source |
| Plain Language Summary | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Unblinded Open-label
| Pemetrexed | Drug | 500 mg/m^2 via IV infusion |
|
| Carboplatin | Drug | AUC 5 mg/mL*min via IV infusion |
|
| H1 Receptor Antagonist | Drug | Administered as rescue medication per approved product label |
|
| H2 Receptor Antagonist | Drug | Administered as rescue medication per approved product label |
|
| Acetaminophen (or equivalent) | Drug | Administered as rescue medication per approved product label |
|
| Dexamethasone (or equivalent) | Drug | Administered as rescue medication per approved product label |
|
| Steroid Mouthwash (dexamethasone or equivalent) | Drug | Administered as rescue medication per approved product label |
|
| Objective Response Rate (ORR) | The objective response rate (ORR) is defined as a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR. The overall response rate for all randomized participants will be reported. | Up to approximately 51 months |
| Duration of Response (DOR) | For participants who demonstrate confirmed CR or PR per RECIST 1.1 as assessed by BICR, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. CR is defined as the disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. | Up to approximately 51 months |
| Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score | The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?" (Item 29) and the Quality of Life (QoL) question "How would you rate your overall quality of life during the past week?" (Item 30) are scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized so that scores range from 0 to 100. A higher value indicates a better level of function. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be reported. | Baseline and up to approximately 6 years |
| Change From Baseline in the Dyspnea (Item 8) Score, on the EORTC QLQ-C30 | The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to the question "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized so that scores range from 0 to 100. A higher value indicates increased severity of symptoms. Change from baseline in dyspnea (EORTC QLQ-C30 Item 8) will be reported. | Baseline and up to approximately 6 years |
| Change from Baseline in the Cough (Item 31) Score, on the EORTC Lung-Cancer specific Quality of Life Questionnaire (QLQ-LC13) | The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates increased severity of symptoms. Change from baseline in cough (EORTC QLQ-LC13 Item 31) will be reported. | Baseline and up to approximately 6 years |
| Change from Baseline in the Chest Pain (Item 40) Score, on the EORTC QLQ-LC13 | The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates increased severity of symptoms. Change from baseline in chest pain (EORTC QLQ-LC13 Item 40) score will be presented. | Baseline and up to approximately 6 years |
| Time to Deterioration (TTD) in Global Health Status/Quality of Life (Items 29 and 30) Combined Score, on the EORTC QLQ-C30 | EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to Items 29 and 30 ("How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. TTD in Global Health Status (GHS)/Quality of Life (QoL) is defined as the time from baseline to the first onset of a ≥10-point decrease from baseline in combined GHS/QoL score. The TTD in GHS/QoL (Items 29 and 30) combined score will be reported. | Baseline and up to approximately 6 years |
| TTD in the Dyspnea (Item 8) Score, on the EORTC QLQ-C30 | EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to the question for Item 8 "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). TTD is defined as the time from baseline to the first onset of a ≥10-point decrease from baseline in score. The TTD in dyspnea score (EORTC QLQ-C30 Item 8) will be reported. | Baseline and up to approximately 6 years |
| TTD in the Cough (Item 31) Score, on the EORTC QLQ-LC13 | The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question for Item 31 "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). TTD is defined as the time from baseline to the first onset of a ≥10-point decrease from baseline in score. The TTD in cough score (EORTC QLQ-C30 Item 31) will be reported. | Baseline and up to approximately 6 years |
| TTD in the Chest Pain (Item 40) Score, on the EORTC QLQ-LC13 | The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question for Item 40 "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. TTD is defined as the time from baseline to the first onset of a ≥10-point decrease from baseline in score. The TTD in chest pain score (EORTC QLQ-C30 Item 40) will be reported. | Baseline and up to approximately 6 years |
| Number of Participants Who Experience One or More Adverse Events (AEs) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported. | Up to approximately 6 years |
| Number of Participants Who Discontinue Study Treatment Due to an AE | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. | Up to approximately 6 years |
| Roseville |
| California |
| 95661 |
| United States |
| Kaiser Permanente - San Francisco ( Site 0056) | San Francisco | California | 94115 | United States |
| Kaiser Permanente - Santa Clara ( Site 0057) | Santa Clara | California | 95051 | United States |
| Kaiser Permanente-Kaiser Permanente ( Site 0036) | Vallejo | California | 94589 | United States |
| Kaiser Permanente - Walnut Creek ( Site 0058) | Walnut Creek | California | 94596 | United States |
| Mid Florida Hematology and Oncology Center ( Site 0005) | Orange City | Florida | 32763 | United States |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0003) | Marietta | Georgia | 30060 | United States |
| University of Michigan ( Site 0009) | Ann Arbor | Michigan | 48109 | United States |
| Cox Medical Center North - Cox Medical Center/ Hematology/Medical Oncology ( Site 0051) | Springfield | Missouri | 65807 | United States |
| Astera Cancer Care ( Site 0032) | East Brunswick | New Jersey | 08816 | United States |
| Stony Brook University-Cancer Center ( Site 0038) | Stony Brook | New York | 11794 | United States |
| Sanford Fargo Medical Center ( Site 0028) | Fargo | North Dakota | 58122 | United States |
| Sanford Cancer Center ( Site 0024) | Sioux Falls | South Dakota | 57104 | United States |
| John Peter Smith Hospital ( Site 0065) | Fort Worth | Texas | 76104 | United States |
| University of Texas MD Anderson ( Site 0063) | Houston | Texas | 77030 | United States |
| Millennium Research & Clinical Development ( Site 0035) | Houston | Texas | 77090 | United States |
| Clinica Adventista Belgrano-Oncology ( Site 0315) | Caba. | Buenos Aires | C1430EGF | Argentina |
| Instituto Alexander Fleming ( Site 0307) | Ciudad Autónoma de Buenos Aires | Buenos Aires | C1426ANZ | Argentina |
| Hospital Británico de Buenos Aires-Oncology ( Site 0304) | Buenos Aires | Buenos Aires F.D. | C1280AEB | Argentina |
| Centro Privado de RMI Río Cuarto S.A. II ( Site 0310) | Río Cuarto | Córdoba Province | X5800ALB | Argentina |
| Instituto de Oncología de Rosario ( Site 0301) | Rosario | Santa Fe Province | S2000KZE | Argentina |
| Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0303) | La Rioja | F5300COE | Argentina |
| Cross Cancer Institute ( Site 0201) | Edmonton | Alberta | T6G 1Z2 | Canada |
| Waterloo Regional Health Network (WRHN) ( Site 0207) | Kitchener | Ontario | N2G 1G3 | Canada |
| Princess Margaret Cancer Centre ( Site 0203) | Toronto | Ontario | M5G 2M9 | Canada |
| McGill University Health Centre ( Site 0204) | Montreal | Quebec | H4A 3J1 | Canada |
| Anhui Provincial Cancer Hospital ( Site 3132) | Hefei | Anhui | 230031 | China |
| Beijing Cancer hospital ( Site 3100) | Beijing | Beijing Municipality | 100142 | China |
| Beijing Peking Union Medical College Hospital-pneumology department ( Site 3107) | Beijing | Beijing Municipality | 100730 | China |
| Chongqing University Cancer Hospital-Medical Oncology ( Site 3128) | Chongqing | Chongqing Municipality | 400030 | China |
| Fujian Cancer Hospital ( Site 3124) | Fuzhou | Fujian | 350014 | China |
| The First Affiliated hospital of Xiamen University ( Site 3125) | Xiamen | Fujian | 361003 | China |
| Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 3102) | Guangzhou | Guangdong | 510515 | China |
| Guangxi Medical University Affiliated Tumor Hospital-Respiratory Oncology ( Site 3103) | Nanning | Guangxi | 530021 | China |
| Harbin Medical University Cancer Hospital ( Site 3109) | Harbin | Heilongjiang | 150081 | China |
| Henan Cancer Hospital ( Site 3105) | Zhengzhou | Henan | 450008 | China |
| Tongji Hospital Tongji Medical,Science & Technology ( Site 3121) | Wuhan | Hubei | 430000 | China |
| Hubei Cancer Hospital ( Site 3122) | Wuhan | Hubei | 430079 | China |
| The Second Xiangya Hospital of Central South University-Oncology ( Site 3104) | Changsha | Hunan | 410011 | China |
| Nanjing Drum Tower Hospital JiangBei International Branch Hospital ( Site 3117) | Nanjing | Jiangsu | 210031 | China |
| The First Affiliated Hospital of Soochow University-Respiratory Department ( Site 3118) | Suzhou | Jiangsu | 215006 | China |
| The Second Affiliated Hospital of Nanchang University ( Site 3119) | Nanchang | Jiangxi | 330006 | China |
| The Second Affiliated Hospital of Xi'an Jiaotong University ( Site 3130) | Xi'an | Shaanxi | 710004 | China |
| Jinan Central Hospital ( Site 3113) | Jinan | Shandong | 250013 | China |
| Shandong Cancer Hospital ( Site 3112) | Jinan | Shandong | 250117 | China |
| Zhongshan Hospital of Fudan University ( Site 3133) | Shanghai | Shanghai Municipality | 200032 | China |
| Shanxi Cancer Hospital ( Site 3114) | Taiyuan | Shanxi | 410013 | China |
| West China Hospital, Sichuan University ( Site 3126) | Chengdu | Sichuan | 610041 | China |
| Sichuan Cancer hospital. ( Site 3127) | Chengdu | Sichuan | 610042 | China |
| The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3101) | Hangzhou | Zhejiang | 310006 | China |
| Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-Medical Oncology ( Site 3106) | Hangzhou | Zhejiang | 310016 | China |
| The First Affiliated Hospital of Wenzhou Medical University-Respiratory department ( Site 3120) | Wenzhou | Zhejiang | 325015 | China |
| FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0600) | Bogotá | Bogota D.C. | 110131 | Colombia |
| Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0606) | Bogotá | Bogota D.C. | 111321 | Colombia |
| Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0601) | Valledupar | Cesar Department | 200002 | Colombia |
| IMAT S.A.S ( Site 0602) | Montería | Departamento de Córdoba | 230002 | Colombia |
| Oncologos del Occidente ( Site 0604) | Pereira | Risaralda Department | 660001 | Colombia |
| Fundacion Valle del Lili- CIC-Oncology CIC ( Site 0605) | Cali | Valle del Cauca Department | 760032 | Colombia |
| Nouvel Hôpital Civil (NHC) ( Site 1302) | Strasbourg | Alsace | 67091 | France |
| Clinique Clairval ( Site 1306) | Marseille | Bouches-du-Rhone | 13009 | France |
| Hopitaux Universitaires Paris Centre-Hopital Cochin-Unité d'Oncologie Thoracique ( Site 1304) | Paris | 75014 | France |
| Gustave Roussy ( Site 1303) | Villejuif | Île-de-France Region | 94805 | France |
| Artemis hospital ( Site 3307) | Gurugram | Haryana | 122001 | India |
| Tata Memorial Hospital-Medical Oncology ( Site 3304) | Mumbai | Maharashtra | 400012 | India |
| Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute-Centre for cancer ( Site 3302) | Mumbai | Maharashtra | 400053 | India |
| All India Institute of Medical Sciences-Department of medical oncology ( Site 3303) | New Delhi | National Capital Territory of Delhi | 110029 | India |
| Indraprastha Apollo Hospitals-APOLLO RESEARCH INNOVATION ( Site 3301) | New Delhi | National Capital Territory of Delhi | 110076 | India |
| Rajiv Gandhi Cancer Institute And Research Centre ( Site 3300) | New Delhi | National Capital Territory of Delhi | 110085 | India |
| Instituto Tumori Giovanni Paolo II-SSD Oncologia Medica per la Patologia Toracica ( Site 1802) | Bari | Apulia | 70124 | Italy |
| Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1800) | Milan | Lombardy | 20133 | Italy |
| Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1803) | Milan | Lombardy | 20141 | Italy |
| Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1804) | Florence | Tuscany | 50134 | Italy |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801) | Roma | 00168 | Italy |
| Fujita Health University Hospital ( Site 3409) | Toyoake | Aichi-ken | 470-1192 | Japan |
| Ehime University Hospital ( Site 3411) | Tōon | Ehime | 791-0295 | Japan |
| National Hospital Organization Kyushu Cancer Center ( Site 3401) | Fukuoka | Fukuoka | 811-1395 | Japan |
| Gunma Prefectural Cancer Center ( Site 3413) | Ōta | Gunma | 373-8550 | Japan |
| Kanazawa University Hospital ( Site 3402) | Kanazawa | Ishikawa-ken | 920-8641 | Japan |
| St. Marianna University Hospital ( Site 3415) | Kawasaki | Kanagawa | 216-8511 | Japan |
| Kanagawa Cancer Center ( Site 3416) | Yokohama | Kanagawa | 241-8515 | Japan |
| Miyagi Cancer Center ( Site 3406) | Natori-shi | Miyagi | 981-1293 | Japan |
| Kansai Medical University Hospital ( Site 3414) | Hirakata | Osaka | 573-1191 | Japan |
| Saitama Prefectural Cancer Center ( Site 3417) | Kitaadachi-gun | Saitama | 362-0806 | Japan |
| Shizuoka Cancer Center ( Site 3405) | Sunto-gun | Shizuoka | 411-8777 | Japan |
| National Cancer Center Hospital ( Site 3408) | Chūō | Tokyo | 104-0045 | Japan |
| Toho University Omori Medical Center ( Site 3407) | Ōta-ku | Tokyo | 143-8541 | Japan |
| Kyushu University Hospital ( Site 3400) | Fukuoka | 812-8582 | Japan |
| Hiroshima City Hiroshima Citizens Hospital ( Site 3419) | Hiroshima | 730-8518 | Japan |
| Niigata Cancer Center Hospital ( Site 3403) | Niigata | 951-8566 | Japan |
| Okayama University Hospital ( Site 3404) | Okayama | 700-8558 | Japan |
| Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 3410) | Osaka | 541-8567 | Japan |
| Osaka Metropolitan University Hospital ( Site 3412) | Osaka | 545-0051 | Japan |
| University Malaya Medical Centre ( Site 3507) | Lembah Pantai | Kuala Lumpur | 59100 | Malaysia |
| National Cancer Institute-Radiotherapy and Oncology ( Site 3504) | Putrajaya | Kuala Lumpur | 62250 | Malaysia |
| Hospital Tengku Ampuan Afzan ( Site 3506) | Kuantan | Pahang | 25100 | Malaysia |
| Hospital Pulau Pinang-Oncology, radiotherapy and palliat ( Site 3501) | George Town | Pulau Pinang | 10450 | Malaysia |
| Sarawak General Hospital-Radiotherapy Unit ( Site 3508) | Kuching | Sarawak | 93586 | Malaysia |
| CIO - Centro de Inmuno-Oncología de Occidente ( Site 0700) | Guadalajara | Jalisco | 44630 | Mexico |
| Arké SMO S.A. de C.V. ( Site 0706) | Mexico City | Mexico City | 06700 | Mexico |
| Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Servicio de Oncología ( Site 0705) | Monterrey | Nuevo León | 64460 | Mexico |
| Oaxaca Site Management Organization S.C. ( Site 0701) | Oaxaca City | 68000 | Mexico |
| Centro de Investigacion Clinica de Oaxaca ( Site 0704) | Oaxaca City | 68020 | Mexico |
| Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2003) | Bydgoszcz | Kuyavian-Pomeranian Voivodeship | 85-796 | Poland |
| Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 2000) | Warsaw | Masovian Voivodeship | 02-781 | Poland |
| Bialostockie Centrum Onkologii ( Site 2010) | Bialystok | Podlaskie Voivodeship | 15-027 | Poland |
| Narodowy Instytut Onkologii - Oddzial w Gliwicach-II Klinika Radioterapi i Chemioterapii ( Site 2002) | Gliwice | Silesian Voivodeship | 44-102 | Poland |
| National Cancer Center ( Site 3803) | Goyang-si | Kyonggi-do | 10408 | South Korea |
| Seoul National University Bundang Hospital ( Site 3807) | Seongnam | Kyonggi-do | 13620 | South Korea |
| The Catholic University Of Korea St. Vincent's Hospital ( Site 3800) | Suwon | Kyonggi-do | 16247 | South Korea |
| Ajou University Hospital ( Site 3813) | Suwon | Kyonggi-do | 16499 | South Korea |
| Pusan National University Yangsan Hospital ( Site 3802) | Pusan | Kyongsangnam-do | 50612 | South Korea |
| Chungbuk National University Hospital ( Site 3804) | Cheongju-si | North Chungcheong | 28644 | South Korea |
| Pusan National University Hospital ( Site 3805) | Busan | Pusan-Kwangyokshi | 49241 | South Korea |
| Keimyung University Dongsan Hospital CRC room 1 ( Site 3814) | Daegu | Taegu-Kwangyokshi | 42601 | South Korea |
| Chungnam national university hospital ( Site 3806) | Junggu | Taejon-Kwangyokshi | 35015 | South Korea |
| The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 3812) | Seoul | 03312 | South Korea |
| Asan Medical Center ( Site 3810) | Seoul | 05505 | South Korea |
| Samsung Medical Center ( Site 3811) | Seoul | 06351 | South Korea |
| Korea University Guro Hospital ( Site 3808) | Seoul | 08308 | South Korea |
| Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2321) | LHospitalet de Llobregat | Barcelona | 08908 | Spain |
| CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 2322) | Santiago de Compostela | La Coruna | 15706 | Spain |
| Hospital Universitario Juan Ramon Jimenez-Oncología Medica ( Site 2323) | Huelva | 21005 | Spain |
| Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 2324) | Seville | 41009 | Spain |
| Karolinska Universitetssjukhuset Solna ( Site 2401) | Stockholm | Stockholm County | 171 64 | Sweden |
| National Cheng Kung University Hospital ( Site 3901) | Tainan | Tainan | 704 | Taiwan |
| Chi Mei Hospital - Liouying Branch ( Site 3909) | Tainan | Tainan | 73657 | Taiwan |
| National Taiwan University Cancer Center (NTUCC) ( Site 3907) | Taipei City | Taipei | 106 | Taiwan |
| Changhua Christian Hospital ( Site 3904) | Changhua | 50006 | Taiwan |
| National Taiwan University Hospital - Hsinchu branch ( Site 3900) | Hsinchu | 300 | Taiwan |
| Chang Gung Memorial Hospital at Kaohsiung ( Site 3905) | Kaohsiung City | 83301 | Taiwan |
| Far Eastern Memorial Hospital ( Site 3912) | New Taipei City | 220 | Taiwan |
| Taichung Veterans General Hospital-Chest ( Site 3910) | Taichung | 40705 | Taiwan |
| National Taiwan University Hospital-Oncology ( Site 3908) | Taipei | 10002 | Taiwan |
| Mackay Memorial Hospital-Chest Medicine ( Site 3902) | Taipei | 10449 | Taiwan |
| Taipei Medical University Hospital ( Site 3903) | Taipei | 110301 | Taiwan |
| Chang Gung Medical Foundation-Linkou Branch-Clinic of Chest Medicine ( Site 3911) | Taoyuan | 333 | Taiwan |
| Faculty of Medicine Siriraj Hospital ( Site 4004) | Bangkoknoi | Bangkok | 10700 | Thailand |
| Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 4006) | Dusit | Bangkok | 10300 | Thailand |
| Faculty of Medicine - Khon Kaen University ( Site 4002) | Muang | Changwat Khon Kaen | 40002 | Thailand |
| Lampang Cancer Hospital ( Site 4000) | Lampang | Changwat Lampang | 52000 | Thailand |
| Ramathibodi Hospital ( Site 4001) | Ratchathewi | Changwat Ratchaburi | 10400 | Thailand |
| Songklanagarind hospital ( Site 4003) | Hat Yai | Changwat Songkhla | 90110 | Thailand |
| Maharaj Nakorn Chiang Mai Hospital ( Site 4005) | Muang | Chiang Mai | 50200 | Thailand |
| Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 2504) | Adana | 01140 | Turkey (Türkiye) |
| Hacettepe Universite Hastaneleri-oncology hospital ( Site 2501) | Ankara | 06230 | Turkey (Türkiye) |
| Memorial Ankara Hastanesi-Medical Oncology ( Site 2505) | Ankara | 06520 | Turkey (Türkiye) |
| Ankara Bilkent Şehir Hastanesi ( Site 2500) | Ankara | 06800 | Turkey (Türkiye) |
| I.E.U. Medical Point Hastanesi-Oncology ( Site 2503) | Izmir | 35575 | Turkey (Türkiye) |
| Hanoi Oncology Hospital ( Site 4198) | Hanoi | Hanoi | 100000 | Vietnam |
| K Hospital - National Cancer Hospital ( Site 4193) | Hanoi | Hanoi | 100000 | Vietnam |
| National Lung Hospital-Oncology Department ( Site 4194) | Hanoi | Hanoi | 100000 | Vietnam |
| Oncology Hospital ( Site 4191) | Ho Chi Minh City | Ho Chi Minh | 700000 | Vietnam |
| Thong Nhat Hospital ( Site 4192) | Tan Binh District | Ho Chi Minh | 700000 | Vietnam |
| Cho Ray Hospital ( Site 4190) | Ho Chi Minh City | 700000 | Vietnam |
| Tam Anh TP.HCM General Hospital ( Site 4196) | Ho Chi Minh City | 700000 | Vietnam |
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068437 | Pemetrexed |
| D016190 | Carboplatin |
| D006633 | Histamine Antagonists |
| D006635 | Histamine H2 Antagonists |
| D000082 | Acetaminophen |
| D003907 | Dexamethasone |
| ID | Term |
|---|---|
| D006147 | Guanine |
| D007042 | Hypoxanthines |
| D011688 | Purinones |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D005971 | Glutamates |
| D024342 | Amino Acids, Acidic |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
| D000600 | Amino Acids, Dicarboxylic |
| D056831 | Coordination Complexes |
| D009930 | Organic Chemicals |
| D018494 | Histamine Agents |
| D018377 | Neurotransmitter Agents |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D045505 | Physiological Effects of Drugs |
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D000814 | Aniline Compounds |
| D000588 | Amines |
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |
Not provided
Not provided